27-Jan-2026
TipRanks (Tue, 27-Jan 6:40 AM ET)
Guardian Pharmacy Services Reiterates 2025 Guidance and Provides 2026 Outlook
Business Wire (Tue, 13-Jan 4:30 PM ET)
Guardian Pharmacy Services, Inc. to Participate in Upcoming J.P. Morgan Healthcare Conference
Business Wire (Mon, 15-Dec 4:30 PM ET)
Guardian Pharmacy Services Reports Third Quarter 2025 Financial Results; Raises Full-Year Guidance
Business Wire (Mon, 10-Nov 4:05 PM ET)
Guardian Pharmacy Services, Inc. to Participate in Upcoming Stephens Investment Conference
Business Wire (Tue, 28-Oct 4:30 PM ET)
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.
Guardian Pharmacy Services Class A trades on the NYSE stock market under the symbol GRDN.
As of January 27, 2026, GRDN stock price declined to $29.71 with 267,665 million shares trading.
GRDN has a beta of 0.29, meaning it tends to be less sensitive to market movements. GRDN has a correlation of 0.01 to the broad based SPY ETF.
GRDN has a market cap of $1.88 billion. This is considered a Small Cap stock.
Last quarter Guardian Pharmacy Services Class A reported $377 million in Revenue and $.25 earnings per share. This beat revenue expectation by $23 million and exceeded earnings estimates by $.03.
The top ETF exchange traded funds that GRDN belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
GRDN has outperformed the market in the last year with a return of +37.7%, while the SPY ETF gained +17.3%. In the last 3 month period, GRDN beat the market returning +2.3%, while SPY returned +1.8%. However, in the most recent 2 weeks GRDN has underperformed the stock market by returning -5.0%, while SPY returned +0.2%.
GRDN support price is $29.61 and resistance is $31.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GRDN shares will trade within this expected range on the day.